Respivert

London, United Kingdom Founded: 2007 • Age: 19 yrs Acquired By Janssen Pharmaceutica
Small molecule drugs for patients with Chronic Obstructive Pulmonary Disease, Cystic Fibrosis and severe asthma.

About Respivert

Respivert is a company based in London (United Kingdom) founded in 2007 was acquired by Janssen Pharmaceutica in June 2010.. Respivert operates in a competitive market with competitors including aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others.

  • Headquarter London, United Kingdom
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Respivert Ltd.
  • Date of Incorporation 18 Dec, 2006
  • Jurisdiction HIGH WYCOMBE, BUCKINGHAMSHIRE
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Funding Insights of Respivert

  • Total Funding
  • Total Rounds 1
  • Last Round
  • First Round
  • Investors Count 1
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2007 Amount Seed - Respivert Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Respivert

Respivert has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Johnson & Johnson Innovative Medicine and Eight Roads Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investment and global platform support for startups.
Founded Year Domain Location
Diversified drugs are manufactured for various therapeutic areas.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Respivert

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Respivert

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Respivert Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Respivert

Respivert operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as aTyr Pharma, ReCode Therapeutics, GEn1E, Enterprise Therapeutics and Ikaria, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Protein biologics are developed for treating rare diseases.
domain founded_year HQ Location
Precision medicines for lung-related diseases are developed.
domain founded_year HQ Location
Developer of therapeutics for the treatment of inflammatory and rare diseases
domain founded_year HQ Location
Developer of therapeutic solutions for the treatment of respiratory diseases such as cystic fibrosis
domain founded_year HQ Location
Therapies for respiratory-related cardiopulmonary disorders are developed.
domain founded_year HQ Location
Respiratory disease drugs for asthma and COPD are developed.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Respivert

Frequently Asked Questions about Respivert

When was Respivert founded?

Respivert was founded in 2007.

Where is Respivert located?

Respivert is headquartered in London, United Kingdom. It is registered at London, England, United Kingdom.

What is the annual revenue of Respivert?

Annual revenue of Respivert is $472.75K as on Dec 29, 2018.

What does Respivert do?

Respivert was established in 2007 in London, United Kingdom, within the biotechnology sector. Small molecule drug discovery is conducted to address chronic respiratory conditions, including chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and severe asthma. Novel treatments are identified through targeted research efforts. Operations are based in the UK, with the companys domain listed as respivert.com. Focus remains on therapeutic advancements for affected patients.

Who are the top competitors of Respivert?

Respivert's top competitors include aTyr Pharma, ReCode Therapeutics and Pulmatrix.

Who are Respivert's investors?

Respivert has 2 investors. Key investors include Johnson & Johnson Innovative Medicine, and Eight Roads Ventures.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available